INDIA – Sputnik V vaccine will now become the third vaccine administered in India after production of the same began in Morepen laboratories following a signed an agreement between the Russian Direct Investment Fund (RDIF) and Morepen Laboratories.
This vaccination campaign program is targeting a population sample size of nearly 93 million individuals above the age of 18 years.
The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
Sputnik V was granted an emergency use authorization in India on April 12, 2021 and the country is the leading production hub for Sputnik V.
Prior to Morepen’s agreement, RDIF had reached agreements earlier with other leading pharmaceutical companies in India – Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech.
In total, agreements with partners in India provide for production of more than 850 million doses of Sputnik V per year.
CoWin is an acronym for Covid Vaccine Intelligent Work and was a platform unveiled back in January 2021 by the union government during a vaccination drive across India.
It also gives healthcare providers backend rights to manage vaccine stock and keep track of the workflow.
Availability of the platform will be made by the Indian government and will be an open source platform as the government said it will not attach any intellectual property rights to it.
It also added that it will not allow the platform to be repackaged or reused for commercial purposes.
According to the Indian Government, close to 140 countries have engaged in the use of the platform with another 50 countries expressing interest in the use of the platform.